Kit for detecting TCF1+BCL11B+CD8 + T cell subset to assist in predicting therapeutic effect of CD3CD19 bispecific antibody and application of kit
By detecting the ratio of TCF1+BCL11B+CD8+T cells, the problem that the existing technology cannot accurately predict the therapeutic efficacy of CD3CD19 bispecific antibody is solved, and effective prediction of the therapeutic efficacy of CD3CD19 bispecific antibody is achieved, helping to select appropriate treatment plans , improves the therapeutic effect.
Patent Information
- Application Number
- CN202410983297.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art cannot accurately predict the efficacy of CD3CD19 bispecific antibody therapy, and new immunotherapy drugs are expensive. It is urgent to explore immune indicators that predict the efficacy of cellular immunotherapy in order to screen suitable patients and carry out more accurate treatments.
Provide a kit and detection method for detecting the subpopulation of TCF1+BCL11B+CD8+ T cells, and assist in predicting the treatment of CD3CD19 bispecific antibody by changing trends in the proportion of TCF1+BCL11B+ double positive cells in CD3+CD8+ T cells in peripheral blood efficacy.
By detecting the ratio of TCF1+BCL11B+CD8+T cells, the efficacy of CD3CD19 bispecific antibody treatment can be effectively predicted, providing theoretical support for clinical applications, helping to choose more appropriate treatment plans, and improving treatment effects.
Smart Images

Figure CN118914562A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, in particular to detecting TCF1 + BCL11B + CD8 + A kit for assisting in predicting the therapeutic efficacy of CD3CD19 bispecific antibodies based on T cell subsets and its application. Background Art
[0002] Acute lymphoblastic leukemia (ALL) is a malignant lymphocyte proliferation disease with blocked early differentiation, mainly B-cell acute lymphoblastic leukemia (B-ALL). The 5-year OS rate of adults is only 30-40%, and the 5-year survival rate after relapse is only 10%. Once relapsed or refractory, the remission rate of multi-drug combination chemotherapy is low, the efficacy is short-lived, it is easy to relapse, and the prognosis is poor.
[0003] In recent years, with the rise and development of cellular immunotherapy methods such as CD3CD19 bispecific monoclonal antibodies, the treatment of adult ALL has been further optimized, not only achieving earlier and deeper remission that is significantly better than conventional chemotherapy, but also creating more opportunities for allogeneic hematopoietic stem cell transplantation and prolonging patient survival. However, 30-40% of patients still have poor efficacy, cannot achieve deep remission or have a short duration of efficacy, and these new immunotherapy drugs are expensive. Therefore, there is an urgent need to explore immune indicators that predict the efficacy of cellular immunotherapy in the clinic, so as to screen more suitable patients and carry out more precise treatment.
[0004] Mechanistic studies have shown that cellular immunotherapy such as CD3CD19 bispecific monoclonal antibodies is highly dependent on the functional status of the patient's T cells. + / CD8 + The distribution, count and proportion changes of T cell subpopulations cannot accurately determine the function of T cells. Currently, there are no T cell immune function indicators in clinical practice to evaluate and predict the efficacy of CD3CD19 bispecific antibodies.
[0005] The transcription factor T cell factor 1 (TCF1) is a protein produced by cytotoxic T lymphocytes (CTL) in response to viral or tumor antigens. + It is necessary for the stem cell-like self-renewal of T cells and the maintenance of long-term effective killing activity of T cells. TCF1 is an important target for regulating the functional state of T cells. It can regulate the differentiation of memory T cells and play an important role in secondary responses. BCL11B is also a key transcription factor involved in T cell differentiation. It can promote the development and differentiation of T cells in the thymus and maintain the activation, proliferation and effector function activity of peripheral T cells. Studies have found that knocking out BCL11B can significantly reduce the expression of naive CD8 +The number of T cells is reduced, the activity of cytotoxic T lymphocytes is inhibited, the expression of exhaustion-related molecules is increased, the generation of memory cells is reduced, and the terminal differentiation of effector T cells is promoted. Therefore, based on the characteristics that TCF1 helps memory cell differentiation and BCL11B helps maintain the effector function of T cells, TCF1 + BCL11B + CD8 + T cells are a newly discovered special type of CD8 that can be used to determine the long-term killing activity of T cells. + T cell subsets. Summary of the invention
[0006] The present invention aims to provide a method for detecting TCF1 + BCL11B + CD8 + The kit and detection method for assisting prediction of CD3CD19 bispecific antibody therapeutic efficacy by T cell subsets can be used to quantify the above T cell subsets, and CD3 + CD8 + TCF1 in T cells + BCL11B + The changing trend of the proportion of double-positive cells indicates the efficacy of treatment, which has a very broad application prospect in assisting the prediction of the efficacy of CD3CD19 bispecific antibody treatment and accurately selecting treatment plans.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides a kit for assisting in predicting the efficacy of a CD3CD19 bispecific antibody, which can be used to detect TCF1 + BCL11B + CD8 + T cell subsets, the kit comprises monoclonal antibodies, fluorescent marker indicators, human peripheral blood lymphocyte separation fluid, transcription factor buffer and phosphate buffer solution.
[0009] Preferably, the monoclonal antibodies include anti-CD3 antibody, anti-CD8 antibody, anti-TCF1 antibody and anti-BCL11B antibody.
[0010] Preferably, the fluorescent labeling indicator includes APC-Cy7, A700, PE and FITC.
[0011] The present invention also provides a detection method for assisting in predicting the efficacy of a CD3CD19 bispecific antibody for purposes other than disease diagnosis or treatment, and the detection is performed using the above-mentioned kit, comprising the following steps:
[0012] The peripheral blood of B-ALL patients was processed to obtain lymphocyte suspension, and then monoclonal antibodies with different fluorescent labels on the membrane surface were added and incubated in the dark. Then, transcription factor buffer was added to resuspend and break the nuclear membrane. After washing, monoclonal antibodies with different fluorescent labels in the cell nucleus were added and incubated again in the dark.
[0013] Preferably, CD3 + CD8 + TCF1 in T cells + BCL11B + When the ratio of double-positive cells is higher than 34.765% and shows an increasing trend, it indicates that the treatment is effective; + CD8 + TCF1 in T cells + BCL11B + When the proportion of double-positive cells is lower than 34.765% and shows a decreasing trend, it indicates that the treatment effect is poor or ineffective.
[0014] Preferably, the monoclonal antibodies with different fluorescences marked on the membrane surface are anti-CD3 antibody and anti-CD8 antibody, and the monoclonal antibodies with different fluorescences marked in the cell nucleus are anti-TCF1 antibody and anti-BCL11B antibody.
[0015] Preferably, the volume ratio of the lymphocyte suspension, anti-CD3 antibody and anti-CD8 antibody is (8-15):1:1.
[0016] Preferably, the volume ratio of the lymphocyte suspension, anti-TCF1 antibody and anti-BCL11B antibody is 100:(0.5-3):(0.5-2).
[0017] Preferably, the cell concentration of the lymphocyte suspension is (3-8)×10 5 pcs / 100μL.
[0018] By adopting the above technical solution, the present invention has the following beneficial effects:
[0019] 1. The present invention utilizes the technical solution to + BCL11B + CD8 + T cell subsets were quantified and CD3 + CD8 + TCF1 in T cells + BCL11B + The proportion of double-positive cells is closely related to the efficacy of CD3CD19 bispecific antibody treatment, which also provides theoretical support for the further clinical application of the above indicators to assist in evaluating the efficacy of CD3CD19 bispecific antibody treatment.
[0020] 2. The present invention shows that the TCF1 in the peripheral blood of B-ALL patients + BCL11B + CD8 + The ratio of T cell subsets was detected, and the cutoff value was 34.765% obtained by ROC curve analysis using the detected values. + BCL11B + T cell subsets in CD3 + CD8 + When the proportion of CD3 T cells in peripheral blood is greater than 34.765%, the possibility of effective treatment is high. + CD8 + TCF1 in T cells + BCL11B + The proportion of double-positive cells was higher than 34.765% and showed an increasing trend, especially on the 14th day after treatment, the level increased significantly, indicating that B-ALL patients had a good therapeutic effect on CD3CD19 bispecific antibody treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Clinical characteristics of 33 patients with relapsed or refractory B-ALL treated with CD3CD19 bispecific antibody;
[0022] Figure 2 TCF1 in peripheral blood of healthy control group and B-ALL patients before treatment + BCL11B + CD8 + The proportion of T cell subsets;
[0023] Figure 3 Flow cytometry was used to detect TCF1 in peripheral blood of B-ALL patients before treatment (D0) and 14 days after treatment (D14). + BCL11B + CD8 + The proportion of T cell subsets;
[0024] Figure 4 Peripheral blood TCF1 of effective and ineffective patients on D0 and D14 + BCL11B + CD8 + The proportion of T cell functional subsets;
[0025] Figure 5 Peripheral blood TCF1 in the control group and B-ALL patients before treatment (D0) and 14 days after treatment (D14) + BCL11B + CD8 + Change trend of T cell subset proportion;
[0026] Figure 6 TCF1 + BCL11B + CD8 + ROC curve of T cell proportion predicting therapeutic effect. DETAILED DESCRIPTION
[0027] The present invention provides a kit for assisting in predicting the efficacy of a CD3CD19 bispecific antibody, which can be used to detect TCF1 + BCL11B + CD8 + T cell subsets, the kit comprises monoclonal antibodies, fluorescent marker indicators, human peripheral blood lymphocyte separation fluid, transcription factor buffer and phosphate buffer solution.
[0028] In the present invention, the cloned antibodies include anti-CD3 antibody, anti-CD8 antibody, anti-TCF1 antibody and anti-BCL11B antibody; the fluorescent labeling indicator includes APC-Cy7, A700, PE and FITC.
[0029] In the present invention, the fluorescent marker of the anti-CD3 antibody is preferably APC-Cy7, the fluorescent marker of the anti-CD8 antibody is preferably A700, the fluorescent marker of the anti-TCF1 antibody is preferably PE, and the fluorescent marker of the anti-BCL11B antibody is preferably FITC.
[0030] In the present invention, the transcription factor buffer preferably includes transcription factor diluent, 4×Fix / PermBuffer, deionized water and 5×Perm / wash Buffer. The preparation method of the transcription factor buffer of the present invention includes: mixing the transcription factor diluent and 4×Fix / Perm Buffer in a volume ratio of 3:1 to obtain 1×Fix / Perm working solution; mixing deionized water and 5×Perm / wash Buffer in a volume ratio of 4:1 to obtain 1×Perm / wash working solution. In the present invention, the transcription factor buffer needs to be prepared before use.
[0031] The present invention also provides a detection method for assisting in predicting the efficacy of CD3CD19 bispecific antibodies for non-disease diagnosis or treatment purposes, which is detected using the above kit and includes the following steps: treating the peripheral blood of B-ALL patients to be tested, obtaining a lymphocyte suspension, adding monoclonal antibodies with different fluorescent labels on the membrane surface, incubating in the dark, then adding transcription factor buffer for resuspending, incubating in the dark at low temperature to break the nuclear membrane, adding monoclonal antibodies with different fluorescent labels on the cell nucleus after washing, incubating again in the dark, and washing the cells for flow cytometry and analysis.+ CD8 + TCF1 in T cells + BCL11B + When the ratio of double-positive cells is higher than 34.765% and shows an increasing trend, it indicates that the treatment is effective; + CD8 + TCF1 in T cells + BCL11B + When the proportion of double-positive cells is lower than 34.765% and shows a decreasing trend, it indicates that the treatment effect is poor or ineffective.
[0032] In the present invention, the processing operation of the peripheral blood of the B-ALL patient to be tested is to dilute the peripheral blood of the B-ALL patient to be tested with PBS and slowly add it to an equal volume of human peripheral blood lymphocyte separation solution, centrifuge according to the density gradient centrifugation method, obtain the buffy coat layer and resuspend it with PBS to obtain a lymphocyte single cell suspension. In the present invention, the density gradient centrifugation method uses a horizontal centrifuge, the speed of the horizontal centrifuge is 1, and the speed of the horizontal centrifuge is 0; the centrifugation time is preferably 25-35min, further preferably 28-32min, and further preferably 30min; the centrifugation speed is preferably 450-550g, further preferably 480-520g, and further preferably 500g. The pH of the PBS in the present invention is preferably 7.2-7.45, more preferably 7.35-7.42, and more preferably 7.4; the concentration of the PBS is preferably 0.005-0.1 M, more preferably 0.008-0.05 M, and more preferably 0.01 M. The cell concentration of the lymphocyte suspension in the present invention is preferably (3-8)×10 5 / 100μL, more preferably (4-7)×10 5 / 100μL, more preferably 5×10 5 pcs / 100μL.
[0033] In the present invention, the light-proof incubation time of the monoclonal antibodies labeled with different fluorescence on the membrane surface is preferably 20-40 min, more preferably 25-35 min, and even more preferably 30 min.
[0034] In the present invention, a transcription factor buffer is added to break the nuclear membrane, and the reaction is preferably carried out on ice in the dark. The time of avoiding light is preferably 40-60 minutes, more preferably 45-55 minutes, and even more preferably 50 minutes.
[0035] In the present invention, the dark-proof incubation time of adding monoclonal antibodies of transcription factors labeled with different fluorescence in the cell nucleus is preferably 40-60 min, more preferably 45-55 min, and even more preferably 50 min.
[0036] In the present invention, the monoclonal antibodies with different fluorescences marked on the membrane surface are anti-CD3 antibody and anti-CD8 antibody, and the monoclonal antibodies with different fluorescences marked in the cell nucleus are anti-TCF1 antibody and anti-BCL11B antibody.
[0037] In the present invention, the volume ratio of the lymphocyte suspension, anti-CD3 antibody and anti-CD8 antibody is preferably (8-15):1:1, further preferably (9-12):1:1, and further preferably 10:1:1; the volume ratio of the lymphocyte suspension, anti-TCF1 antibody and anti-BCL11B antibody is preferably 100:(0.5-3):(0.5-2), further preferably 100:(0.8-2):(0.8-1.3), and further preferably 100:1:1.
[0038] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0039] The APC Cy7-labeled mouse anti-human CD3, A700-labeled mouse anti-human CD8, PE-labeled mouse anti-human TCF1, FITC-labeled mouse anti-human BCL11B and PBS buffer in the present invention were purchased from Biolegend, and the transcription factor buffer kit was purchased from BD Pharmingen.
[0040] Example 1 (one)
[0042] Subject screening criteria: Patients with relapsed / refractory B-ALL who were diagnosed with B-ALL according to the WHO diagnostic criteria through MICM testing and treated with CD3CD19 bispecific antibodies in Henan Cancer Hospital from April 2022 to April 2024 were collected (relapsed B-ALL patients had bone marrow or peripheral blood primitive cells ≥5% after achieving complete remission or the patient's bone marrow cell morphology was in a remission state but minimal residual disease changed from negative to positive; refractory B-ALL patients did not achieve complete remission after one course of standard induction chemotherapy).
[0043] There were 33 subjects, including 11 males and 22 females, with an age range of 3-77 years old. Figure 1 At the same time, peripheral blood samples from 8 healthy volunteers of matched age were collected as controls. This part of the research plan has been approved by the ethics committee of our institution. (two)
[0045] Blood was collected after the patients signed informed consent forms. Peripheral blood samples were collected before CD3CD19 bispecific antibody treatment (D0) and 14 days after treatment (D14). All specimens were obtained from fasting intravenous EDTA anticoagulation in the early morning.
[0046] The peripheral blood collected from healthy people and patients with relapsed / refractory B-ALL was used to separate lymphocytes using human peripheral blood lymphocyte separation solution. 2 mL of peripheral blood and PBS were diluted in a 1:1 ratio, and then slowly added to 2 mL of human mononuclear lymphocyte separation solution, and then centrifuged at a speed of 0 to 1,500g for 30 minutes, and the middle white film layer was carefully aspirated into a new centrifuge tube. Count under a microscope, and take 5×10 5 Cells were added with PBS, centrifuged at 500g for 5 min, the supernatant was discarded, and 100μL PBS was added to resuspend the cells to form a lymphocyte single cell suspension. Two flow cytometry tubes were prepared for each sample, one as the test tube and one as the same type tube, and 100μL of the single cell suspension prepared above was added to each tube.
[0047] Add the corresponding cell membrane surface fluorescent labeled antibodies to the test tube and the isotype tube, including 10μL APC Cy7-CD3 and 10μL A700-CD8 of mouse anti-human, mix gently, and incubate at low temperature and away from light for 30min. Pre-cool the PBS buffer containing 2% FBS in a 4℃ refrigerator for standby use. After incubation, take 2mL PBS and add it to the cells incubated with the above membrane antigen labeling, mix it by blowing, place it in a centrifuge, centrifuge it at 4℃, 500g, wash it for 5min, and discard the supernatant. After washing the cells with PBS, add fresh pre-made transcription factor buffer (1mL of 1×Fix / Perm working solution) to resuspend the cells, mix well, and react on ice in the dark for 50min to fully break the nuclear membrane. After breaking the nuclear membrane, add 2mL of 1×Perm / wash working solution to the flow tube to wash the cells twice (at 4℃, 500g, centrifuge for 5min, and discard the supernatant). Then, 100 μL of 1×Perm / wash working solution was added to resuspend the cell pellet, and 1 μL of TCF1-PE and BCL11B-FITC antibodies were added to label the antigens in the nucleus. After mixing, the cells were incubated at low temperature and away from light for 50 min. The cells were washed twice with 1×Perm / wash working solution, and the supernatant was discarded. After washing the cells, 350 μL of PBS buffer containing 2% FBS was added to resuspend the cell pellet, and the cells were detected using a FACS Calibur (Becton Dickinson, San Jose, CA) flow cytometer to obtain the fluorescence-labeled TCF1 + BCL11B + CD8 +The data of T cell subsets were processed by Navios flow cytometer software (Beckman Coulter, Brea, CA, USA). The analysis data were summarized and the differences of each group of data were calculated using Prism 10 software, and the P value was calculated by student t test.
[0048] The preparation process of the transcription factor buffer is as follows: the transcription factor diluent and 4×Fix / Perm Buffer are mixed at a ratio of 3:1 to obtain a 1×Fix / Perm working solution; deionized water and 5×Perm / washBuffer are mixed at a ratio of 4:1 to obtain a 1×Perm / wash working solution. The reagents need to be prepared before use.
[0049] Compared with the control group, peripheral blood TCF1 + BCL11B + CD8 + The proportion of T cell subsets was significantly lower than that of peripheral blood TCF1 in the control group + BCL11B + CD8 + T cell subset ratio ( Figure 2 TCF1 in peripheral blood of B-ALL patients before treatment (D0) and 14 days after treatment (D14) + BCL11B + CD8 + T cell subsets results Figure 3-5 The results showed that 14 days after treatment, the peripheral blood CD3 + CD8 + TCF1 in T cells + BCL11B + The proportion of double-positive cells showed an increasing trend, which was significantly higher than that before treatment; on the contrary, the CD3 + CD8 + TCF1 in T cells + BCL11B + The proportion of double-positive cells continued to decrease, significantly lower than that of patients with good efficacy. The ROC curve can be used to determine the cutoff value (the value in the upper left corner of the ROC curve) to be 34.765, which also shows that the detection of TCF1 + BCL11B + Double positive cells have a certain sensitivity and specificity in predicting the therapeutic efficacy of CD3CD19 bispecific antibodies ( Figure 6 The above experimental results show that by detecting TCF1 in peripheral blood of B-ALL patients + BCL11B + CD8 +The proportion of T cell subsets can help predict the efficacy of CD3CD19 bispecific antibody therapy. + CD8 + TCF1 in T cells + BCL11B + When the proportion of double-positive cells is higher than 34.765% and shows an increasing trend, it indicates that the treatment is effective.
[0050] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A kit for assisting in predicting the efficacy of a CD3CD19 bispecific antibody. It is characterized in that This kit can be used to detect TCF1 + BCL11B + CD8 + T cell subsets, the kit comprises monoclonal antibodies, fluorescent marker indicators, human peripheral blood lymphocyte separation fluid, transcription factor buffer and phosphate buffer solution.
2. The kit according to claim 1, It is characterized in that The monoclonal antibodies include anti-CD3 antibody, anti-CD8 antibody, anti-TCF1 antibody and anti-BCL11B antibody.
3. The kit according to claim 1, It is characterized in that The fluorescent labeling indicators include APC-Cy7, A700, PE and FITC.
4. A detection method for assisting in predicting the efficacy of a CD3CD19 bispecific antibody for non-disease diagnosis or treatment purposes, It is characterized in that Detection using the kit according to any one of claims 1 to 3 comprises the following steps: The peripheral blood of B-ALL patients was processed to obtain lymphocyte suspension, and then monoclonal antibodies with different fluorescent labels on the membrane surface were added, incubated in the dark, and then transcription factor buffer was added to resuspend and break the nuclear membrane. After washing, monoclonal antibodies with different fluorescent labels in the cell nucleus were added, and incubated again in the dark; CD3 in peripheral blood + CD8 + TCF1 in T cells + BCL11B + When the ratio of double-positive cells is higher than 34.765% and shows an increasing trend, it indicates that the treatment is effective; + CD8 + TCF1 in T cells + BCL11B + When the proportion of double-positive cells is lower than 34.765% and shows a decreasing trend, it indicates that the treatment effect is poor or ineffective.
5. The detection method according to claim 4, It is characterized in that The monoclonal antibodies with different fluorescences marked on the membrane surface are anti-CD3 antibody and anti-CD8 antibody, and the monoclonal antibodies with different fluorescences marked in the cell nucleus are anti-TCF1 antibody and anti-BCL11B antibody.
6. The detection method according to claim 4, It is characterized in that The volume ratio of the lymphocyte suspension, anti-CD3 antibody and anti-CD8 antibody is (8-15):1:1; The volume ratio of the lymphocyte suspension, anti-TCF1 antibody and anti-BCL11B antibody is 100:(0.5-3):(0.5-2).
7. The detection method according to claim 4, It is characterized in that The cell concentration of the lymphocyte suspension is (3-8)×10 5 pcs / 100μL.
